IP Library › Granted Patent US 12,497,593
Granted Patent B2
US 12,497,593 · App. 16/563,190 · Granted Dec 16, 2025

Generation of hematopoietic progenitor cells from human pluripotent stem cells

Inventors: James A. Thomson (Madison, WI); Jue Zhang (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0647A61K40/11A61K40/15A61K40/22A61K40/32A61K40/418A61K40/42C12N5/0636C12N5/0645C12N5/0646C12N2501/115C12N2501/125C12N2501/145C12N2501/165C12N2501/2303C12N2501/42C12N2501/999C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,593
App. No.
16/563,190
Granted
Dec 16, 2025
Kind
B2
Abstract

Methods for generating and using hematopoietic progenitor cells are described.

Claims (8)

1 . A method for obtaining CD34+ CD45+ hematopoietic progenitor cells, the method comprising: culturing human pluripotent stem cells (hPSCs) at a low density seeding, wherein the low density seeded hPSCs are seeded at a density of between about 6×10 3 to about 3×10 4 cells/cm 2 in a first serum-free, albumin-free, chemically-defined culture medium for about 2 days, whereby a cell population comprising mesoderm cells is obtained, wherein the mesoderm cells exhibit increased SMAD1/5/8 phosphorylation compared to mesoderm cells obtained from high density seeded hPSCs, wherein the high density seeded hPSCs are seeded at a density of between about 6×10 4 to about 3×10 5 cells/cm 2 and cultured in a condition comprising the first serum-free, albumin-free, chemically-defined culture medium for about 2 days; culturing the mesoderm cells in a second chemically-defined culture medium that comprises fibroblast growth factor 2 (FGF2), vascular endothelial growth factor A (VEGF-A), a Notch agonist, a TGFP inhibitor, and an inhibitor of inositol monophosphatase for about 6 days, whereby a cell population comprising hemangioblast cells is obtained; and culturing the hemangioblast cells in a third chemically-defined culture medium that comprises insulin, FGF2, VEGF-A, and the Notch agonist for about 3-4 days, whereby a cell population comprising CD34+ CD45+ hematopoietic progenitor cells is obtained, wherein the Notch agonist is selected from the group consisting of Resveratrol (3,4′,5 trihydroxystilbene), valproic acid, or suberoyl bishydroxamic acid, wherein the TGFP inhibitor is SB431542, and wherein the inhibitor of inositol monophosphatase is L-690,330 ([1-(4-Hydroxyphenoxy)ethylidene]bisphosphonic acid).

2 . The method of claim 1 , wherein the mesoderm cells express one or more mesodermal marker selected from the group consisting of Brachyury (T), EMOS, FOXA2, MIXL1, MSX1, and MSX2.

3 . The method of claim 1 , wherein the first serum-free, albumin-free chemically-defined cell culture medium comprises Bone Morphogenetic Protein 4 (BMP4), Activin A, and an activator of Wnt/β-catenin signaling.

4 . The method of claim 1 , wherein the human pluripotent stem cells are selected from the group consisting of human embryonic stem cells and human induced pluripotent stem cells.

5 . The method of claim 1 , wherein the low density seeded human pluripotent stem cells are seeded at a density of about 1×10 4 cells/cm 2 .

6 . The method of claim 3 , wherein the activator of Wnt/β-catenin signaling is a Gsk3 inhibitor.

7 . The method of claim 6 , wherein the Gsk3 inhibitor is selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.

8 . The method of claim 1 , wherein the low density seeded human pluripotent stem cells are seeded at a density of about 2.0×10 4 cells/cm 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2019
From: THOMSON, JAMES; ZHANG, JUE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 050398/0347 →
Continuity (2)
Provisional Application 62728408 · Sep 7, 2018
Related Publication 20200080059A1 · Mar 12, 2020
References Cited (81)
US 6143292A · Slavin · 2000 [cited by applicant]
US 6326198B1 · Emerson · 2001 [cited by applicant]
US 6383481B1 · Ikehara · 2002 [cited by applicant]
US 6441053B1 · Klein · 2002 [cited by examiner]
US 6447765B1 · Horwitz · 2002 [cited by applicant]
US 6916654B1 · Sims · 2005 [cited by applicant]
US 8268620B2 · Thomson · 2012 [cited by applicant]
US 8440461B2 · Thomson · 2013 [cited by applicant]
US 9938499B2 · Slukvin · 2018 [cited by applicant]
US 20110027886A1 · Han et al. · 2011 [cited by applicant]
US 20130217117A1 · Thomson · 2013 [cited by applicant]
US 20140057355A1 · Thomson · 2014 [cited by applicant]
US 20140134195A1 · Russell · 2014 [cited by applicant]
US 20140248696A1 · Zhang · 2014 [cited by examiner]
US 20160186137A1 · Thomson et al. · 2016 [cited by applicant]
US 20160244719A1 · Thomson · 2016 [cited by applicant]
US 20170130202A1 · Nakahata et al. · 2017 [cited by applicant]
US 20170240861A1 · Murry · 2017 [cited by examiner]
JP 2010213576 · 2010 [cited by applicant]
JP 2015519890 · 2015 [cited by applicant]
JP 2015522290 · 2015 [cited by applicant]
JP 2016512031 · 2016 [cited by applicant]
JP 2016512960 · 2016 [cited by applicant]
WO 1998045479 · 1998 [cited by applicant]
WO 2010096746 · 2010 [cited by applicant]
WO WO2010096746A1 · 2010 [cited by examiner]
WO WO2013163171 · 2013 [cited by applicant]
WO WO2014013255 · 2014 [cited by applicant]
WO WO2014134412 · 2014 [cited by applicant]
WO WO2014165131 · 2014 [cited by applicant]
WO 2016114723 · 2016 [cited by applicant]
WO 2016123100 · 2016 [cited by applicant]
WO 2015199127 · 2017 [cited by applicant]
WO WO2017078807 · 2017 [cited by applicant]
WO WO2018146297 · 2018 [cited by applicant]
Wang et al (“TGFβ inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy,” Cell Research (2012) 22:194-207). [cited by examiner]
Wang et al 2009 (“WNT and BMP signaling are both required for hematopoietic cell development from human ES cells,” Stem Cell Research vol. 3, Issues 2-3, Sep.-Nov. 2009, pp. 113-125. [cited by examiner]
Kennedy et al (“Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation culture,” Blood, Apr. 1, 2007, vol. 109, No. 7). [cited by examiner]
Lengerke et al (“Hematopoietic Development from Human Induced Pluripotent Stem Cell,” Hematopoietic Stem Cells VII: Ann. N.Y. Acad. Sci. 1176: 219-227 (2009). [cited by examiner]
Huang et al (“Haematopoietic differentiation is inhibited when Notch activity is enhanced in FLK1+ mesoderm progenitors,” Stem Cell Research (2013) 11, 1273-1287). [cited by examiner]
Cerdan et al (“Novel roles for Notch, Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells,” Int. J. Dev. Biol. 54: 955-964 (2010). [cited by examiner]
Heinz et al (“Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells,” Stem Cells Translational Medicine 2015;4:1064-1072… [cited by examiner]
Zhang et al (“Functional characterization of human pluripotent stem cell-derived arterial endothelial cells,” PNAS E6072-E6078| Published online Jul. 10, 2017) (Year: 2017). [cited by examiner]
Pearson S, et al. The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF. Development. Mar. 13, 2008; 135(8):1525-35. doi: 10.1242/dev… [cited by examiner]
Bai H, et al. The balance of positive and negative effects of TGF-β signaling regulates the development of hematopoietic and endothelial progenitors in human pluripotent stem cells. Stem Cells Dev. Jun. 13, 2013;22(20):… [cited by examiner]
Heinz N, et al. Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells. Stem Cells Transl Med. Jul. 9, 2015; 4(9):1064-72… [cited by examiner]
International Search Report for PCT/US2019/049955, dated Jan. 27, 2020. [cited by applicant]
Wang et al. TGF[beta] inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy. Cell Research. 2011. vol. 22, No. 1: 194-207. [cited by applicant]
Pearson et al. The STepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and FEGF. Development. 2008. vol. 135, No. 8: 1525-1535. [cited by applicant]
Baba, Y. et al. Constitutively active ß-catenin confers multi-lineage differentiation potential on lymphoid and myeloid progenitors. Immunity 23:599-609 (2005). [cited by applicant]
Berridge, M. J., et al. “Neural and developmental actions of lithium: a unifying hypothesis.” Cell 59.3 (1989): 411-419. [cited by applicant]
Bray, S.J. (2016). Notch signalling in context. Nat Rev Mol Cell Biol 17, 722-735. [cited by applicant]
Challa-Malladi, M., et al. “Combined genetic inactivation of ß2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.” Cancer cell 20.6 (2011): 728-740. [cited by applicant]
Chen, G., et al. “Chemically defined conditions for human iPSC derivation and culture.” Nature methods 8.5 (2011): 424. [cited by applicant]
Deuse et al., “Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogenic recipients,” Nature Biotechnology, vol. 37, 252-258, 2019. [cited by applicant]
Ebert, A. D., et al. “Induced pluripotent stem cells from a spinal muscular atrophy patient.” Nature 457.7227 (2009): 277. [cited by applicant]
GenBank: AAH11177.2 VEGFA protein, partial [ [cited by applicant]
GenBank: AAH65522.2 Vegfa protein, partial [ [cited by applicant]
GenBank: CAA61107.1, beta-catenin [ [cited by applicant]
GenBank: X87838, [cited by applicant]
Goldman, D. C., et al. “BMP4 regulates the hematopoietic stem cell niche.” Blood 114.20 (2009): 4393-4401. [cited by applicant]
Gornalusse, G. G., et al. “HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.” Nature biotechnology 35.8 (2017): 765. [cited by applicant]
Hagen, T., et al. “Expression and characterization of GSK-3 mutants and their effect on ß-catenin phosphorylation in intact cells.” Journal of Biological Chemistry 277.26 (2002): 23330-23335. [cited by applicant]
Handgretinger, R., et al. (2018). The potential role of gammadelta T cells after allogeneic HCT for leukemia. Blood 131, 1063-1072. [cited by applicant]
Howden, S. E., et al. “Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy.” Proceedings of the National Academy of Sciences 108.16 (2011): 6537-6542. [cited by applicant]
Inman, G. J., et al. “SB-431542 is a potent and specific inhibitor of transforming growth factor-ß superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.” Molecular pharmacology 62.1 (2002… [cited by applicant]
June, et al., “CAR T cell immunotherapy for human cancer,” Science, 359, 1361-1365, 2018. [cited by applicant]
Knorr, D.A., et al. (2013). Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2, 274-283. [cited by applicant]
Lis, R., et al. (2017). Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature 545, 439-445. [cited by applicant]
Lu, B., et al. “Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration.” Stem cells 27.9 (2009): 2126-2135. [cited by applicant]
Mehta, R.S., et al. (2018). Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol 9, 283. [cited by applicant]
Pan, D. (2010). The hippo signaling pathway in development and cancer. Dev Cell 19, 491-505. [cited by applicant]
Riolobos, L., et al. “HLA engineering of human pluripotent stem cells.” Molecular Therapy 21.6 (2013): 1232-1241. [cited by applicant]
Sugimura, R., et al. (2017). Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545, 432-438. [cited by applicant]
Thomson, J. A., et al. “Embryonic stem cell lines derived from human blastocysts.” science 282.5391 (1998): 1145-1147. [cited by applicant]
Wang, Y., et al. (2009). WNT and BMP signaling are both required for hematopoietic cell development from human ES cells. Stem Cell Res 3, 113-125. [cited by applicant]
Wu, D., et al. (2017). Human gammadeltaT-cell subsets and their involvement in tumor immunity. Cell Mol Immunol 14, 245-253. [cited by applicant]
Yu, J., et al. “Human induced pluripotent stem cells free of vector and transgene sequences.” Science 324.5928 (2009): 797-801. [cited by applicant]
Yu, J., et al. “Induced pluripotent stem cell lines derived from human somatic cells.” science 318.5858 (2007): 1917-1920. [cited by applicant]
Zhang, J., et al. (2017). Functional characterization of human pluripotent stem cell-derived arterial endothelial cells. Proc Natl Acad Sci U S A 114, E6072-E6078. [cited by applicant]
Vereide et al., “An expandable, inducible hemangioblast state regulated by fibroblast growth factor,” Stem Cell Reports, 3(6): 1043-57 (2014). [cited by applicant]